NCT05847049

Eplerenone, Aflibercept and Topical Nepafenac Serous Foveal Deta Chment in Central Serous Chorioretinopathy

Influence of Combined Eplerenone , Intravitreal Aflibercept and Topical Nepafenac Therapy on Serous Foveal Detachment in Central Serous Chorioretinopathy (CSCR)

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 16 (actual)
• Sponsor: Dar El Oyoun Hospital · Academic / Other
• Sex: All
• Age: 16 Years – 60 Years
• Healthy volunteers: Not accepted

Summary

describing the influence of; combined Eplerenone, intravitreal Aflibercept, and topical Nepafenac; on serous foveal detachment in eyes with CSCR

Detailed description

Retrospective Review of records of eyes with Central serous chorioretinopathy (CSCR) that have been treated in the period between 2015 and 2021 After checking inclusion and exclusion criteria; we will enroll all cases that have been treated by the combination of eplerenone, intravitreal aflibercept and topical nepafenac. Investigators collected and recorded the following data: * Age * Gender * Systemic hypertension (present or not) * Smoking (Yes / No) * Best corrected visual acuity (BCVA) (baseline, final) * Central macular thickness (CMT) (baseline, final) * Serous detachment Height (SDH) (baseline, final) * Duration of Follow-up ( in months)

Conditions

• Central Serous Chorioretinopathy

Interventions

Type	Name	Description
OTHER	Eplerenone , Intravitreal Aflibercept and Topical nepafenac therapy	Eplerenone , Intravitreal Aflibercept and Topical nepafenac therapy

Timeline

• Start date: 2023-02-28
• Primary completion: 2023-03-25
• Completion: 2023-04-06
• First posted: 2023-05-06
• Last updated: 2023-05-06

Locations

1 site across 1 country: Egypt